TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by Mackenzie Financial Corp

Mackenzie Financial Corp increased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 73.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 828,147 shares of the company's stock after buying an additional 349,403 shares during the period. Mackenzie Financial Corp owned about 2.47% of TransMedics Group worth $51,635,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Janney Montgomery Scott LLC purchased a new stake in shares of TransMedics Group during the fourth quarter worth approximately $239,000. Cornerstone Wealth Management LLC purchased a new stake in shares of TransMedics Group during the fourth quarter worth approximately $231,000. Sachetta LLC purchased a new stake in shares of TransMedics Group during the fourth quarter worth approximately $40,000. Perigon Wealth Management LLC increased its position in shares of TransMedics Group by 212.4% during the fourth quarter. Perigon Wealth Management LLC now owns 14,277 shares of the company's stock worth $828,000 after purchasing an additional 9,707 shares in the last quarter. Finally, Clear Creek Financial Management LLC purchased a new stake in shares of TransMedics Group during the fourth quarter worth approximately $352,000. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Trading Down 1.1%

Shares of TransMedics Group stock traded down $1.39 during trading hours on Friday, hitting $126.30. The company's stock had a trading volume of 294,546 shares, compared to its average volume of 1,492,920. The firm has a fifty day moving average of $94.15 and a 200-day moving average of $78.41. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The stock has a market cap of $4.27 billion, a price-to-earnings ratio of 134.36 and a beta of 1.91.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same quarter in the prior year, the company earned $0.35 EPS. TransMedics Group's revenue was up 48.2% on a year-over-year basis. Research analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on TMDX. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, April 23rd. Oppenheimer upped their target price on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Canaccord Genuity Group restated a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Piper Sandler restated an "overweight" rating and issued a $125.00 target price (up from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, TransMedics Group has a consensus rating of "Moderate Buy" and an average price target of $126.70.

Insider Buying and Selling

In related news, Director Edward M. Basile sold 5,000 shares of the stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $126.45, for a total transaction of $632,250.00. Following the transaction, the director now owns 2,866 shares of the company's stock, valued at approximately $362,405.70. This represents a 63.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Weill sold 732 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director now directly owns 12,134 shares in the company, valued at approximately $1,503,159.92. The trade was a 5.69% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,732 shares of company stock valued at $1,416,710. Corporate insiders own 7.00% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.